Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Breast cancer
Phase 1 HLD-0117 oral RIPTAC with no disclosed target/MOA in ER+ metastatic breast cancer
*No disclosed MOA. We do not include details of trials without this basic information.*
NCT07524855 First-in-human - New trial Spotlight
Prostate cancer
Phase 1/2 AZD8359 STEAP2-targeted CD8-guided T cell–engaging antibody in metastatic prostate cancer
This first-in-human, modular, open-label Phase 1/2 study (CRIUS-1) from AstraZeneca evaluates AZD8359, a T cell–engaging antibody designed to direct CD8 T cells toward STEAP2-expressing prostate cancer cells (STEAP2…
NCT07529717 First-in-human - New trial
Brain and CNS tumors
Phase 2 mirdametinib MEK1/2 inhibitor with radiotherapy in NF1-altered high‑grade glioma
University of Alabama at Birmingham (UAB) is running this Phase 2, open-label, parallel, multi-arm study testing mirdametinib—an oral small-molecule MEK1/MEK2 inhibitor (MAPK-pathway blockade downstream of…
NCT07521657 Exploratory - New trial
Brain and CNS tumors
Phase 2 JZP3507 (ONC206) dopamine receptor D2 antagonist small molecule in recurrent high-grade meningioma.
This Phase 2, open-label study sponsored by Jazz Pharmaceuticals evaluates JZP3507 (ONC206), an oral small-molecule dopamine receptor D2 (DRD2) inhibitor, in adults with recurrent/progressive World Health…
NCT07533942 Exploratory - New trial Spotlight
Colorectal cancer
Phase 1 BAY 3771249 KRAS G12D-selective inhibitor ± EGFR antibody cetuximab in mCRC
Bayer (with partner Kumquat Biosciences) is running an open-label Phase 1 master protocol testing BAY 3771249 (also referenced as KQB548), an oral small-molecule KRAS G12D-selective inhibitor, given alone or combined…
NCT07535112 Exploratory - New trial
Brain and CNS tumors
Phase 1 rTMS targets motor-network rebalancing via theta-burst neuromodulation (cTBS/iTBS)
This single-center, open-label pilot study evaluates whether image-guided repetitive transcranial magnetic stimulation (rTMS) can accelerate motor recovery after brain tumor surgery by modulating cortical…
NCT07530536 Exploratory - New trial
Lymphoma
Phase 1 pomalidomide (IMiD cereblon modulator) to boost CD19 CAR‑T persistence
This single-center, single-arm Phase 1 pilot at University of Michigan Rogel Cancer Center evaluates whether short-course pomalidomide given after CD19-directed CAR‑T can safely improve CAR‑T expansion/persistence…
NCT07532525 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 haploidentical HSCT using cyclophosphamide/busulfan or fludarabine/TBI conditioning (DNA-damaging alkylators)
This National Cancer Institute (NIH Clinical Center) Phase 2, prospective, open-label transplant protocol tests whether individualized (“tailored”) dosing of conditioning chemotherapy and key supportive-care drugs…
NCT07524530 Exploratory - New trial Spotlight
Myeloproliferative neoplasms
Phase 1 PRT12396 mutant-selective JAK2V617F inhibitor (allosteric JH2 “pseudokinase” inhibitor) in PV/MF
Prelude Therapeutics is running a first-in-human, open-label, multi-center Phase 1 dose-escalation/expansion study testing PRT12396, an oral, twice-daily small molecule designed to selectively inhibit the JAK2 V617F…
NCT07469891 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1a/1b BMS-986504 MTA-cooperative PRMT5 inhibitor combo basket in MTAP-deleted tumors.
This Phase 1a/1b, disease-specific basket study tests BMS-986504 (navlimetostat), an MTA-cooperative PRMT5 inhibitor designed to exploit the MTAP-deletion/MTA accumulation vulnerability, in combination with standard…
NCT07532902 Exploratory - New trial
Multiple solid tumors
Phase 1 E303 Nectin-4–targeting antibody-drug conjugate in refractory solid tumors.
This first-in-human, open-label, multicenter Phase 1 study evaluates E303 (also referenced as SBE303), a Nectin-4–targeting antibody-drug conjugate (ADC) being developed by Samsung Bioepis. The trial uses sequential…
NCT07524348 First-in-human - Trial result Spotlight
Non-small cell lung cancer
Trastuzumab Deruxtecan (HER2 ADC) posts 50–56% ORR in HER2-mutant mNSCLC
Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody–drug conjugate with a topoisomerase-I payload; in the dose-blinded, randomized Phase 2 DESTINY-Lung02 (NCT04644237), previously treated HER2-mutant mNSCLC…
NCT04644237 - Trial result Spotlight
Acute myeloid leukemia and MDS
CD371/SAVVY/IL-18 Armored CAR T Clears 3/5 r/r AML in First-in-Human Pilot
CD371/SAVVY/IL-18 is a CLEC12A (CD371/CLL-1)–targeted, IL-18–secreting CAR T built with a mutated CD28 costimulatory domain to limit exhaustion; in the Phase I dose-finding study NCT06017258, 5 patients with…
NCT06017258 - Trial result
Head and neck cancer
Lifileucel/LN-145 (autologous TIL) posts 11% ORR and 76% DCR in R/M HNSCC
One-time autologous tumor-infiltrating lymphocyte (TIL) therapy—cryopreserved lifileucel (22- vs 16-day manufacturing) and a PD-1–selected TIL product (LN-145-S1)—was given after non-myeloablative lymphodepletion…
NCT03083873 - Trial result Spotlight
Sarcoma and GIST
Abemaciclib (CDK4/6) + temozolomide/irinotecan delivers durable CR in 5th-relapse ARMS
Abemaciclib is an oral CDK4/6 inhibitor; in JPCS Part A (Phase 1b, NCT04238819) an 8-year-old with 5th-relapse, PAX3-FOXO1, CDK4-amplified ARMS received abemaciclib 55 mg/m² BID continuously with temozolomide 100…
NCT04238819 - Trial result
Colorectal cancer
FOLFOXIRI+Bevacizumab (VEGF) extends PFS vs doublets in unresectable liver-only/right-sided/RAS or BRAF-mut mCRC
FOLFOXIRI+bevacizumab (VEGF blockade) was tested as first-line therapy in an individual-patient pooled analysis of 4 randomized trials (TRIBE, TRIBE2, CHARTA, STEAM) focused on initially unresectable liver-only,…
- New trial Spotlight
Non-small cell lung cancer
Phase II randomized: durvalumab + monalizumab (NKG2A) vs durva + oleclumab (CD73) → RT in PD-L1-high, unresectable stage III
Montefiore compares two chemo-free “priming” pairs (AstraZeneca and Innate Pharma) prior to risk-adapted radiotherapy in treatment-naïve stage III (PD-L1 ≥50%). PACIFIC established durvalumab after chemoradiation;…
NCT07146230 Exploratory - New trial Spotlight
Prostate cancer
Phase Ib ^177Lu-PSMA-617 + liver-directed therapy for mCRPC with liver mets
UCSF evaluates Novartis’ PSMA-targeted Lu-177 radioligand therapy with site-directed treatment (TACE/ablation/Y-90 TARE) for mCRPC patients who’ve progressed on at least one AR-pathway inhibitor. PSMA RLT is a go-to…
NCT07145177 Exploratory - New trial
Prostate cancer
Phase Ib Elekta UNITY MR-Linac salvage SBRT + short ADT after prior EBRT
NYU Langone trials MR-guided SBRT with online adaptive replanning plus 4–6 months of ADT in biopsy-proven local recurrence post-EBRT. Salvage options (surgery/cryo/HDR/SBRT) can control disease but GU toxicity is a…
NCT07142967 Exploratory - New trial
Cervical and other gynecologic cancers
Phase I pBI-11 HPV16/18 DNA vaccine ± TA-HPV immunotherapy in advanced disease
Johns Hopkins (SKCCC) randomizes adjuvant PVX7 regimens using pBI-11 (therapeutic DNA vaccine to HPV16/18 from Papivax) via scarification or IM, with/without TA-HPV. After chemo/IO for recurrent/metastatic disease,…
NCT06315257 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase I NSC-CRAd-S-pk7 oncolytic adenovirus ± NAC-amide → then SOC chemoradiation/TTFields
Northwestern assesses repeated intratumoral NSC-CRAd-S-pk7 (± NAC-amide) followed by standard temozolomide-radiation and tumor-treating fields (Novocure) in newly diagnosed grade 3/4 glioma. Despite the Stupp…
NCT06169280 First-in-human - New trial
Multiple myeloma
Phase 1/2 ABBV-453 (BCL-2 inhibitor) ± daratumumab/dexamethasone (± pomalidomide) in R/R MM
AbbVie tests ABBV-453 across dose-escalation/expansion, alone and on CD38/IMiD backbones (with a Japanese monotherapy cohort). Late-line MM cycles through IMiDs/PIs/anti-CD38, with venetoclax often used off-label in…
NCT06953960 First-in-human - New trial
Kidney cancer
Phase 1b/2 zanzalintinib (c-MET/VEGFR TKI) + belzutifan (HIF-2α) in recurrent ccRCC during/after adjuvant anti-PD-(L)1
Within KEYMAKER-U03 (Merck), this doublet targets angiogenesis (VEGFR/MET) plus hypoxia signaling (HIF-2α) in patients recurring on/after adjuvant IO. Frontline RCC has moved to IO+TKI, and belzutifan has traction…
NCT07049926 Exploratory - New trial
Kidney cancer
Phase I nivolumab/ipilimumab ± EXL01 live biotherapeutic in mRCC
City of Hope evaluates whether gut-microbiome modulation (EXL01 from Exeliom Biosciences) augments response to the established nivo/ipi doublet (BMS). Many patients fail to achieve deep or durable benefit on IO;…
NCT07128680 Exploratory - New trial
Uterine (endometrial) cancer
Phase II enfortumab vedotin (nectin-4 ADC) in recurrent/persistent endometrial carcinoma post-IO
Open-label testing of EV in a post-progression setting, including after pembrolizumab-based regimens, where options are often limited to chemo or lenvatinib+pembro backbones. EV’s success in urothelial cancer plus…
NCT07139977 Exploratory - New trial
Pancreatic cancer
Phase II adaptive SBRT + defactinib (FAK) + avutometinib (RAF/MEK clamp) in advanced PDAC
Washington University and Verastem Oncology explore stromal and MAPK co-targeting wrapped around adaptive SBRT, with a safety lead-in. Unresectable PDAC still leans on FOLFIRINOX or gem/nab-paclitaxel with modest…
NCT07126158 Exploratory - New trial Spotlight
Lymphoma
Phase I MB-CART19.1 (CD19 CAR-T) for CNS lymphoma
MSK identifies the maximum safe dose of on-site–manufactured CD19 CAR-T for primary/secondary CNS lymphoma (incl. DLBCL), using CliniMACS Prodigy (Miltenyi Biomedicine), leukapheresis, conditioning chemo, and…
NCT07137494 Exploratory - New trial
Colorectal cancer
Phase II fruquintinib (VEGFR) + FOLFIRI in second-line mCRC
SCRI adds selective VEGFR inhibition to Q2-week FOLFIRI. In 2L mCRC, FOLFIRI ± bevacizumab or anti-EGFR (for RAS/BRAF-WT left-sided) is typical; fruquintinib may extend VEGF blockade beyond bev to sustain disease…
NCT07011576 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase II p-HIPEC with cisplatin + paclitaxel during gastrectomy for high-risk gastric/GEJ
Mayo Clinic evaluates heated intraperitoneal cisplatin/paclitaxel delivered intra-op alongside D2 gastrectomy to cut peritoneal relapse. Even with peri-op FLOT, peritoneal spread is the Achilles’ heel; p-HIPEC aims…
NCT07139951 Exploratory - New trial
Myeloproliferative neoplasms
Phase II Pacritinib JAK2/FLT3 inhibitor bridge in accelerated/blast-phase MPN
University of Washington is testing pacritinib (a JAK2/FLT3 inhibitor) layered onto standard hypomethylating agents (azacitidine or decitabine/cedazuridine) to raise transplant eligibility in accelerated/blast-phase…
NCT07148947 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.